Active — Not RecruitingPhase 1

Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

China30 participantsStarted 2025-01-17

Plain-language summary

This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.

Who can participate

Age range75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.Availability of an HLA-matched sibling donor, unrelated donor, or haploidentical donor.
✓.Age ≥ 14 years. 4.Liver function: ALT and AST ≤ 2.5 × upper limit of normal (ULN), total bilirubin ≤ 2 × ULN.
✓.Renal function: serum creatinine ≤ ULN. 6.Absence of uncontrolled infection or severe psychiatric/psychological disorders.
✓.Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. 8.Signed informed consent. 9.Diagnosis of grade II acute GVHD as assessed by the modified Glucksberg grading criteria for acute GVHD.

What they're measuring

Graft-Versus-Host Disease-Free, Relapse-Free Survival

Timeframe: 1 years after treatment

Trial details

NCT IDNCT07576010

SponsorDaihong Liu

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-30

View on ClinicalTrials.gov More Acute Graft-versus-host Disease trials